Agilent Technologies, Inc. (NYSE:A) Shares Acquired by Nebula Research & Development LLC

Nebula Research & Development LLC increased its stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 100.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,696 shares of the medical research company's stock after acquiring an additional 3,854 shares during the quarter. Nebula Research & Development LLC's holdings in Agilent Technologies were worth $1,034,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of A. Flynn Zito Capital Management LLC increased its position in Agilent Technologies by 3.8% during the 4th quarter. Flynn Zito Capital Management LLC now owns 1,871 shares of the medical research company's stock worth $251,000 after purchasing an additional 69 shares during the period. IFP Advisors Inc grew its holdings in Agilent Technologies by 17.7% during the fourth quarter. IFP Advisors Inc now owns 458 shares of the medical research company's stock worth $62,000 after acquiring an additional 69 shares during the period. Tiemann Investment Advisors LLC raised its position in Agilent Technologies by 5.6% in the fourth quarter. Tiemann Investment Advisors LLC now owns 1,423 shares of the medical research company's stock worth $191,000 after acquiring an additional 75 shares in the last quarter. Rothschild Investment LLC lifted its holdings in Agilent Technologies by 19.2% in the fourth quarter. Rothschild Investment LLC now owns 491 shares of the medical research company's stock valued at $66,000 after acquiring an additional 79 shares during the period. Finally, CIBC Private Wealth Group LLC boosted its position in shares of Agilent Technologies by 1.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 7,479 shares of the medical research company's stock worth $1,025,000 after purchasing an additional 87 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on A. TD Cowen boosted their price objective on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a report on Thursday, April 10th. Robert W. Baird cut their price target on Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating for the company in a research note on Thursday, February 27th. Jefferies Financial Group lowered their price objective on shares of Agilent Technologies from $135.00 to $116.00 and set a "hold" rating on the stock in a research note on Monday, April 21st. Wells Fargo & Company cut their target price on shares of Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating for the company in a research report on Thursday, April 17th. Finally, Barclays lowered their price target on shares of Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $143.00.

Insider Activity

In other news, Director Daniel K. Podolsky sold 1,819 shares of Agilent Technologies stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $116.46, for a total value of $211,840.74. Following the completion of the transaction, the director now owns 35,737 shares in the company, valued at approximately $4,161,931.02. This trade represents a 4.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the sale, the vice president now directly owns 21,786 shares in the company, valued at approximately $2,657,456.28. This represents a 8.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Agilent Technologies Trading Down 1.1 %

Shares of A traded down $1.14 during mid-day trading on Thursday, reaching $106.46. The company had a trading volume of 1,523,116 shares, compared to its average volume of 1,875,860. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $155.35. The firm has a fifty day simple moving average of $114.66 and a 200-day simple moving average of $130.34. The stock has a market cap of $30.35 billion, a price-to-earnings ratio of 24.47, a price-to-earnings-growth ratio of 3.03 and a beta of 1.19. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.27 by $0.04. The company had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. On average, sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.54 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st were given a $0.248 dividend. This represents a $0.99 annualized dividend and a dividend yield of 0.93%. The ex-dividend date was Tuesday, April 1st. Agilent Technologies's payout ratio is 22.76%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.